CAH stock news · Cardinal Health, Inc.
Get alerts for CAH
Follow Cardinal Health, Inc. (CAH) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CAHMorgan Stanley has increased its price target for Cardinal Health to $286.
Good for CAHCardinal Health's Morgan Stanley analyst raised its stock target and kept an Overweight rating, a positive signal for the shares. The report gives no new company results.
Following Q4 results, analysts boost their price targets for Cardinal Health.
NeutralCardinal Health reported mixed Q4 results, beating earnings expectations but missing on sales. Analysts responded positively by raising their price targets, reflecting confidence in the company's growth trajectory and operational strength.
Cardinal Health announces that it currently exclusively caters to almost 50% of the cell and gene therapy sector.
Good for CAHCardinal Health's stock surged nearly 7% following a strong earnings report that exceeded expectations, alongside a significant expansion in its cell and gene therapy market share. The company's strategic initiatives, including a $5 billion share buyback and a renewed agreement with Kroger, further bolster its growth outlook.
US equities show varied performance; Cardinal Health's stock soars following Q4 earnings announcement.
Good for CAHCardinal Health's shares surged after the company reported Q4 adjusted earnings of $2.91 per share, significantly exceeding market expectations of $2.42. Despite missing sales estimates, the strong earnings performance has positively influenced investor sentiment and stock price.
Cardinal Health Inc. discloses operational outcomes and financial status (CAH).
NeutralCardinal Health has filed a Form 8-K detailing its results of operations and financial condition, which is crucial for investors to assess the company's current performance and future outlook. This filing may lead to immediate trading activity as investors react to the disclosed information.
Cardinal Health Inc. engages in a significant definitive agreement (CAH).
Good for CAHCardinal Health has filed a Form 8-K detailing its entry into a material definitive agreement, which suggests potential changes in its financial obligations and could lead to strategic shifts in operations. This news is likely to be viewed positively by investors as it may indicate growth or expansion opportunities.
Anticipation builds for Cardinal Health's Q4 earnings report as Wall Street's top analysts adjust their forecasts.
NeutralCardinal Health is set to report its Q4 earnings, with analysts adjusting their price targets in anticipation. While some analysts have raised their targets, one has lowered theirs, indicating mixed sentiment ahead of the earnings release.
CARDINAL HEALTH INC: Changes in Leadership with Departure and Appointment of Officers; Election of Directors; Compensation Details for Certain Executives (CAH).
NeutralCardinal Health Inc. has filed a Form 8-K detailing the departure and appointment of certain officers, which could lead to changes in leadership strategy and operational direction. This news is critical as it may influence investor sentiment and the company's future performance.